347results about "Allergen ingredients" patented technology

Described herein are novel and improved antibodies that bind to thymic stromal lymphopoietin (TSLP) and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP. In certain aspects, described herein are methods of treating asthma by administering anti-TSLP antibodies.

The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-α-1,3-galactose, a known red meat allergen, and methods for use thereof.

Provided are a cat allergen polypeptide fragment and use thereof. Fel d1 is divided into a plurality of polypeptides of 10-20 amino acids, which are then co-expressed with VLPs proteins; subsequently, hyperimmune serum of Fel d1 is used for screening; and 2 Fel d1 polypeptides with relatively good immunogenicity are successfully screened. The 2 polypeptides are used for co-expression with VLPs and then formulated into a vaccine to immunize a cat. The secretion amount of Fel d1 in the cat saliva is detected, and the secretion amount of Fel d1 can be reduced by 80% or more. The described polypeptides effectively reduce the secretion amount of the Fel d1 protein in the cat saliva, and reduce the spread of Fel / d1 in the air.

The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

The present invention provides compositions and methods for inducing antigen-specific tolerance in a subject. In one embodiment, the present invention provides a composition comprising an apoptotic body and an epitope of an antigen. Also provided herein are methods of preparing and administering the composition. The composition and methods provided herein can induce antigen-specific tolerance in a subject.

The present invention includes compositions, including epitope megapools, and methods for detecting the presence of cow milk allergen(s), specifically T cell epitopes for T cells responsive to one or more cow milk peptides or proteins comprising, consisting of, or consisting essentially of: one or more peptides or proteins selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081), or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein comprising one or more amino acid sequences selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such protein(s) or peptide(s).

This application discloses a feline allergen Fel d1 egg yolk antibody and its preparation method and application, comprising: obtaining PCR amplification products through PCR amplification; constructing a recombinant plasmid by ligating the PCR amplification products with pET-28a(+); transforming the recombinant plasmid into Rosetta competent cells to obtain transformants; obtaining recombinant antigens by extracting proteins from the transformants; obtaining a subunit vaccine by mixing and emulsifying the recombinant antigens with white oil adjuvant; administering the subunit vaccine to laying hens to obtain immunized egg yolk liquid; adding Tris-HCl buffer and polyethylene glycol to the egg yolk liquid and centrifuging to collect the protein aqueous phase; filtering the protein aqueous phase to obtain a filtrate, adding polyethylene glycol, mixing, centrifuging to collect the precipitate; mixing the precipitate with PBS buffer, adding ammonium sulfate, and centrifuging to obtain the egg yolk antibody. This invention solves the problem that the safety and economy of existing feline allergy treatment methods cannot be simultaneously achieved.

Provided are a recombinant cat allergen, a pharmaceutical composition therefor, a preparation method therefor, and a use thereof. Compared with naturally extracted allergen products, the recombinant cat allergen has multiple advantages in desensitization immunotherapy and allergen diagnosis for cat allergic diseases. For example, high purity and high uniformity are achieved; a pure protein / peptide having specified properties and quality is defined; the allergenicity, immunogenicity, and tolerability of the allergen are predetermined; production is performed according to GMP standards; the production of a specified quantity and concentration in a reproducible manner is enabled; product standardization and quality controllability are achieved; regulatory requirements for modern pharmaceuticals and vaccines are met; and when used for diagnosis, the allergen can identify allergen molecules that truly cause allergic reactions and reveal cross-reactivity, and when used for treatment, the allergen enables targeted allergen immunotherapy for a patient, avoiding the influence of non-allergenic substances in an extract, improving the safety, and facilitating precise diagnosis, precise administration, etc.

The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also 5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and / or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.

Prokaryotic expression of a cat allergen protein chimeric peptide cFel d 1 based on a T-cell antigen epitope, and preparation of an egg yolk antibody. A chimeric peptide cFel d 1, comprising a 25-41th-position amino acid residue segment, a 46-59th-position amino acid residue segment, a 85-98th-position amino acid residue segment, a 132-140th-position amino acid residue segment and a 145-153th-position amino acid residue segment of a cat allergen Fel d 1 antigen amino acid residue. Experiments prove that an antibody obtained after immunizing animals by means of the chimeric peptide cFel d 1 has high titer, can specifically bind to a cat allergen complete Fel d 1 protein, and is superior to a polyclonal antibody prepared by means of a complete Fel d 1 protein (the titer is 8 times higher).

The invention provides a Fujian oyster allergen Craa a2T cell epitope peptide and application thereof. The amino acid sequence of the Fujian oyster allergen Craa a2T cell epitope peptide is shown as SEQ ID NO: 1 or SEQ ID NO: 2. The method comprises the following steps: predicting seven simulated T cell epitopes of Craa2 by utilizing a bioinformatics technology; identifying two T cell epitopes of Craa2 by combining a CD4 + T cell proliferation experiment with MHC-II molecular docking simulation; an RBL-2H3 cell degranulation experiment is adopted, and the anti-allergic activity of the Cra a 2T cell epitope peptide is further verified. The obtained epitope peptide can be used for developing a hybrid peptide preparation and a desensitization preparation for treating oyster allergy, and a new strategy is provided for researching allergen specific immunotherapy and simultaneously exerting an anti-allergic effect.

A kit (100) and method (200) are provided for administering an active ingredient (112) to a subject to elicit a response. The kit comprises a first container (110) with an active ingredient (112) and a second container (120) with an adjuvant (122). The containers permit the ingredients to be admixed to form a compounded preparation for delivery into the subject's tissue. The active ingredient can comprise an allergen. The kit can also include temperature control and mixing components, potentially involving a third container (130). The method comprises providing the kit (100), admixing the ingredients, and injecting the compounded form into the subject's tissue such as a lymph node. The injection can be monitored and repeated. The approach can elicit various responses such as desensitization according to the type of active ingredient used. Overall, the kit (100) and method (200) provide targeted delivery of active ingredients to efficiently provoke a localized response in the subject.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

In one embodiment, the present disclosure provides hypoallergenic peanut allergen AraH6 variants, in which at least one epitope recognized by an anti-AraH6 antibody has been altered, thereby reducing or eliminating antibody binding to the peanut allergen. Such hypoallergenic peanut allergen variants retain immunogenicity and can be used in methods for treating and reducing the severity of peanut allergies in subjects (patients) with peanut allergies.

The present invention pertains to specific bioparticules at the surface of which are expressed multimeric protein. The bioparticles according to the present invention comprise an envelope consisting of a plasma membrane; and at least one type I or II transmembrane fusion protein anchored in said membrane, said fusion protein comprising successively a) a first monomer of a multimeric protein of interest, b) a coiled-coil domain or oligomerization sequence; and c) a domain for anchoring in the plasma membrane, consisting of a transmembrane segment and a cytosolic segment. Fragments a) and b) are exposed at the surface of the bioparticle, and fragment a) is bound to a second monomer of said multimeric protein by means of a bond which is not a peptide bond. The bioparticles according to the present invention can be used in therapy such as immunotherapy. The present invention also pertains to methods for producing such bioparticles.

The present invention provides highly effective and safe means capable of preventing or treating an egg allergy in infants. An oral immunotolerance agent or a food composition for preventing or treating an egg allergy according to the present invention contains a degraded product of heat-denatured egg white with an aspartic protease (e.g. pepsin) or a metal protease (e.g. thermolysin).

The present invention relates to an mRNA vaccine comprising at least one RNA molecule encoding at least one cytokine (preferably IL-4, IL-13, or a fragment thereof) and at least one T cell epitope for treating or preventing disorders associated with aberrant IL-4 and / or IL-13 expression or activity, in particular asthma, atopic dermatitis and allergic disorders.

This invention provides a peanut allergen peptide, its screening method, and its application. Phage display technology is used to screen for conformational epitopes of Ara h5 and Ara h8 proteins. Polyclonal IgE and IgG antibodies against the target proteins are prepared by immunizing BALB / c mice with Ara h5 and Ara h8 proteins as antigens. ELISA and dotted immunoblotting detection revealed that the titers of polyclonal IgG and IgE against Ara h5 and Ara h8 proteins were 1:64000 and 1:320, respectively, and the antibodies exhibited specificity. Using the antibodies as targets, phage display technology screened the conformational epitope sequences of Ara h5 protein as WETIYSR and FHWWYLK. The conformational epitopes of Ara h8 protein were FPYMKFV, FPYMKFR, SMFARID, and SFHWWLF.

The present invention relates to a modified virus-like particle (VLP) of Cucumber Mosaic Virus (CMV) comprising at least one fusion protein, wherein the at least one fusion protein comprises or preferably consists of b) a chimeric CMV polypeptide, wherein the chimeric CMV polypeptide comprises or preferably consists of (iii) a CMV polypeptide, wherein the CMV polypeptide comprises a coat protein of CMV; and (iv) an antigen polypeptide, wherein the antigen polypeptide is inserted into the CMV polypeptide, wherein the insertion of the antigen polypeptide is between amino acid residues corresponding to position 84 and position 85 of SEQ ID NO: 62 of the CMV polypeptide; and (iii) a T helper cell epitope, wherein the T helper cell epitope replaces an N-terminal region of the CMV polypeptide, and wherein preferably the N-terminal region of the CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO: 62.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

An embodiment of the present invention provides a biocompatible, thermosensitive hydrogel composition for subcutaneous or intramuscular injection, the hydrogel comprising a poloxamer, such as poloxamer 338, poloxamer 188, or poloxamer 407, or a mixture thereof, and the composition includes a therapeutic protein or antigen embedded in the composition for sustained release.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

A nucleic acid vector composition comprising: one or more enzymes and / or one or more fragments thereof, a nucleic acid, one or more particles comprising hydrolyzable silicon, and one or more lipids, as well as related products, medical uses, and methods.

The present invention provides a novel antigen for soy allergy, a diagnostic method and kit for soy allergy, a pharmaceutical composition containing the antigen, soybeans or soybean products from which the antigen has been removed, and a tester for determining the presence or absence of soybean antigen in a target object. [Solution] A polypeptide is provided which comprises a polypeptide containing at least one amino acid sequence selected from a specific group, which specifically binds to IgE antibodies in patients with polypeptide allergies, and which has 500 or fewer amino acid residues.

To provide safe and effective means to induce tolerance to cedar pollen antigens (e.g., CRYJ1 and CRYJ2) in subjects that suffer from Japanese cedar pollinosis, or in subjects at risk for developing Japanese cedar pollinosis, taking account of the substantial prevalence of the disease, particularly in Japan and neighboring countries, and the likelihood of antibody cross-reactivity between conifer pollens.SOLUTION: The present invention provides compositions comprising particles with a negative zeta potential that encapsulate one or more epitopes associated with Japanese cedar pollen. Methods of inducing immunological tolerance to Japanese cedar pollen by administering the particles are also provided.SELECTED DRAWING: Figure 1

The present invention provides a novel antigen for soy allergy, a method and kit for diagnosing soy allergy, a pharmaceutical composition containing the antigen, soybeans or soybean products from which the antigen has been removed, and a tester for determining the presence or absence of soybean antigen in a target object. [Solution] The diagnostic kit of the present invention comprises at least one of the proteins identified as (1) to (8), or at least one of the proteins identified as (1α) to (55α).